Alector, Inc. (NASDAQ:ALEC) Financial and Operational Highlights

Core Insights - Alector, Inc. is a clinical-stage biotechnology company focused on therapies for neurodegenerative diseases, particularly Alzheimer's and Parkinson's, utilizing its Alector Brain Carrier platform [1] Financial Performance - Alector reported a quarterly loss of $0.34 per share, which was better than the expected loss of $0.39, resulting in a 13.71% earnings surprise [3][6] - The company's revenue for the quarter ending December 2025 was $6.24 million, exceeding expectations by 103.43%, but down significantly from $54.24 million reported a year ago [4][6] - Alector has consistently surpassed consensus revenue estimates in three of the last four quarters [4] Financial Position - Alector's financial position includes $256 million in cash, cash equivalents, and investments, which is expected to support operations through 2027 [5] - The company's current ratio is 3.83, indicating a strong ability to cover short-term liabilities [5][6] - However, the enterprise value to operating cash flow ratio is -1.36, suggesting challenges in generating positive cash flow from operations [5]